Changzhou National High-Tech Zone Holds Groundbreaking Ceremony: 70 New Production and Service Facilities to be Built This Year

Changzhou National High-Tech Zone notes construction is planned to start in 2021. The 70 projects represent a total investment of US$8.9 billion, of which, US$3.3 billion is expected to be made this year.

The projects include 47 manufacturing facilities with a total investment of US$4.6 billion, of which US$1.6 billion is earmarked for 2021. Emerging and specialized sectors account for more than 80% of what will be produced at the new facilities.

The projects are comprised of 17 at the municipal level, 51 at the district level and 2 categorized as key in supporting the transportation infrastructure. Sectors covered by the new projects include smart energy, new materials, electric vehicles, core auto parts, new medicines and medical devices, and next-generation information technology, as well as modern service sectors providing science and innovation platforms. The facilities are aimed at improving the ecological environment, enhancing industrial capacity and improving people’s livelihoods.

The event was held on the grounds where the Phase II project of Intersurgical Medical Device’s plant will be built. Officials from ten sub-districts gave short presentations on the number, value and structure of the investment projects in their respective jurisdictions.

Intersurgical Medical Device (Changzhou) Co., Ltd. is a wholly-owned subsidiary of Intersurgical, the largest manufacturer of respiratory and anesthesia medical devices in Europe. In 2014, the company invested in its Phase I project in the Life and Health Industrial Park of Changzhou National High-Tech Zone. The Phase II project has a total investment of UKP 36 million (approx. US$49 million), and a projected annual production capacity of 110 million units of medical equipment such as respiratory therapy devices, respiratory filtration devices and anesthesia masks, as well as 100 sets of trimming molds.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.